SpyGlass Pharma, Inc.
SGP- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0001778922
No open-market purchases or sales by SpyGlass Pharma, Inc. insiders were filed in the last 90 days; 52 institutions reported holding it in 13F filings for Q2 2026, worth $581.1M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +17 vs. previous quarter
- 52
- 13F valueReported value at the end of Q2 2026
- $581.1M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding SGP, Q2 2026
No superinvestor reported holding SGP at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by SpyGlass Pharma, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 11, 2026 (view filing)5:15 PM ET | Feb 9 | 2 days | RA Capital Healthcare Fund LP and 4 othersDirector, 10% Owner | PPurchase | +3.69M | $16.00 | +$59.0M | New position2.05M after | 2 lots |
| Feb 11, 2026 (view filing)4:30 PM ET | Feb 9 | 2 days | New Enterprise Associates 17, L.P. and 2 others10% Owner | PPurchase | +937.5K | $16.00 | +$15.0M | +18.4%6.04M after | Duplicate filing |
| Feb 11, 2026 (view filing) | Feb 9 | 2 days | Khan Bilal ArshadDirector | PPurchase | +20.0K | $16.00 | +$320.0K | +367.0%25.4K after | |
| Feb 11, 2026 (view filing) | Feb 9 | 2 days | Khan Bilal ArshadDirector | PPurchase | +115.0K | $16.00 | +$1.84M | +84.3%251.4K after | |
| Feb 11, 2026 (view filing) | Feb 9 | 2 days | Pardo Geoffrey BDirector | PPurchase | +312.5K | $16.00 | +$5.00M | +16.7%2.19M after | |
| Feb 11, 2026 (view filing) | Feb 9 | 2 days | Behbahani AliDirector, 10% Owner | PPurchase | +937.5K | $16.00 | +$15.0M | +18.4%6.04M after | Duplicate filing |
| Feb 11, 2026 (view filing) | Feb 9 | 2 days | Florence Anthony A. Jr.10% Owner | PPurchase | +937.5K | $16.00 | +$15.0M | +18.4%6.04M after | Duplicate filing |
| Feb 11, 2026 (view filing) | Feb 9 | 2 days | Baskett Forest10% Owner | PPurchase | +937.5K | $16.00 | +$15.0M | +18.4%6.04M after | Duplicate filing |
| Feb 11, 2026 (view filing) | Feb 9 | 2 days | Yang Rick10% Owner | PPurchase | +937.5K | $16.00 | +$15.0M | +18.4%6.04M after | Duplicate filing |
| Feb 11, 2026 (view filing) | Feb 9 | 2 days | Makhzoumi Mohamad10% Owner | PPurchase | +937.5K | $16.00 | +$15.0M | +18.4%6.04M after | Duplicate filing |
Top 10 13F holders, Q2 2026
The largest institutional positions in SpyGlass Pharma, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 8,021,117 | $178.6M | 1.55% | 00.0% | Unchanged |
| NEA Management Company, LLC | 7,392,301 | $164.6M | 10.36% | 00.0% | Unchanged |
| Sands Capital Ventures, LLC | 2,500,012 | $55.7M | 9.07% | 00.0% | Unchanged |
| Samsara BioCapital, LLC | 2,109,953 | $47.0M | 3.86% | 00.0% | Unchanged |
| BlackRock, Inc. | 711,712 | $15.8M | 0.00% | +566,973+391.7% | Added |
| Price T Rowe Associates Inc | 674,143 | $15.0M | 0.00% | −30,297−4.3% | Reduced |
| Vestal Point Capital, LP | 670,000 | $14.9M | 0.35% | +3,240+0.5% | Added |
| JPMorgan Chase & Co | 629,739 | $13.6M | 0.00% | +52,630+9.1% | Added |
| Deerfield Management Company, L.P. (Series C) | 550,000 | $12.2M | 0.13% | 00.0% | Unchanged |
| Millennium Management LLC | 507,257 | $11.3M | 0.01% | +38,463+8.2% | Added |